Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Autoimmune disease stories

Oct 16, 2026

Novartis terminates Fabhalta mid-stage trial in lupus nephritis

Novartis has ended a mid-stage clinical trial testing Fabhalta in patients with lupus nephritis, citing 'strategic considerations' according to federal clinical trial records.

Oct 16, 2026·2 sources
00
Oct 2, 2026

Biogen's daxdilimab reduces disease activity in moderate-to-severe discoid lupus trial

Biogen's experimental monoclonal antibody daxdilimab demonstrated significant reduction in disease activity with favorable safety profile in Phase 2 trial for patients with moderate-to-severe discoid lupus erythematosus.

Oct 2, 2026·2 sources
00
Sep 23, 2026

Roche kidney disease drug succeeds in Phase 3 trial for IgA nephropathy

Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.

Sep 23, 2026·3 sources
00
Sep 22, 2026

Amgen's dazodalibep succeeds in Phase 3 trial for Sjögren's disease

Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.

Sep 22, 2026·4 sources
00
Sep 2, 2026

Teva's celiac disease drug prevents intestinal damage in gluten challenge trial

Teva's experimental drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge in a mid-stage study, representing potential progress for a condition with no current drug treatments.

Sep 2, 2026·2 sources
00
Sep 1, 2026

Alumis experimental lupus drug fails primary endpoint in phase 3 trial

Alumis reported its experimental TYK2 inhibitor failed to meet the main goal of a late-stage lupus trial, though the company plans to advance the drug in a smaller subset of patients.

Sep 1, 2026·2 sources
00

Novartis pauses autoimmune cell therapy trials after three patient deaths

Novartis temporarily halted enrollment and treatment in eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after three patients died. Bristol Myers Squibb programs were also paused.

Sep 1, 2026·3 sources
00
Aug 28, 2026

Priovant receives first FDA approval for targeted tablet in dermatomyositis

Priovant Therapeutics secured its first FDA approval for a targeted tablet treatment for dermatomyositis, a rare autoimmune disease affecting muscles and skin.

Aug 28, 2026·2 sources
00
Jun 26, 2026

European Medicines Agency Recommends Revoking Amgen's Tavneos Over Data Integrity Issues

The European Medicines Agency recommended withdrawing marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing allegedly incorrect and misleading data used in the approval process and lack of benefits outweighing risks.

Jun 26, 2026·3 sources
00
Apr 11, 2026

CAR-T Therapy Shows Continued Success in Autoimmune Diseases Five Years After Lupus Breakthrough

Five years after initial lupus breakthrough, CAR-T cell therapy continues to demonstrate remissions in autoimmune diseases, generating significant research investment and experimentation beyond its original cancer applications.

Apr 11, 2026·1 source
00
Apr 6, 2026

Scripps Research Develops New Anti-Inflammatory Drug Class That Preserves Immune Function

Scripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.

Apr 6, 2026·1 source
00

FDA Delay Forces Small Biotech Company to Shut Down Operations

A small biotech company was forced to wind down operations after the FDA abruptly postponed a key meeting for four months, despite reaching a clinical trial agreement in February that came too late.

Apr 6, 2026·2 sources
00

Top claims

  • ▪Endpoints News first reported on October 16, 2026 that Novartis terminated its mid-stage trial for Fabhalta in lupus nephritis
  • ▪The mid-stage Fabhalta study that Novartis terminated evaluated whether the oral medication was safe and effective for treating lupus nephritis when added to standard medical care
  • ▪The U.S. Food and Drug Administration first approved Novartis's drug Fabhalta in 2023 to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria

Topics

Clinical trialsDrug Policy, Pricing & ApprovalDrug Approval and Clinical TrialsClinical Trial Design & EvaluationPharmaClinical evaluationPharmaceutical IndustryDiet & nutritionDrug developmentLifestyle, Wellness and NutritionClinical trial endpointsCAR T-cell therapyNeurological disordersFDA drug approvalFDA drug approval processNew drug application (NDA) processEuropean UnionAging biology expertsLongevity & biohackingInflammation reduction & immune effectsDrug Classes & Treatment AccessLongevity biotech founders

Related entities

DermatologyLupusTargeted therapiesRare DiseaseGermanyInflammationImmunologyRheumatoid arthritis